Professor Patrick Harter is a faculty member at the Institute of Neuropathology, Ludwig Maximilian University of Munich (LMU), where he leads research in neuro-oncology and molecular diagnostics of CNS tumors. His work focuses on glioblastoma, meningioma, and brain metastasis, with emphasis on epigenetic mechanisms like DNA methylation and metabolic adaptations in the tumor microenvironment. Research interests span: Molecular classification of brain tumors using DNA methylation profiling Therapeutic targeting of BRAF/MEK and PI3K/Akt/mTOR pathways Role of hypoxia and metabolic plasticity in treatment resistance Liquid biopsy development for non-invasive tumor monitoring His recent publications demonstrate a strong trend toward integrating epigenetic, metabolic, and immunotherapeutic approaches. Articles frequently explore: Novel biomarkers for tumor grading and prognosis Mechanisms of therapy resistance in gliomas Impact of tumor microenvironment on metastasis
Olga G. Troyanskaya is a Professor of Computer Science and the Lewis-Sigler Institute for Integrative Genomics at Princeton University. She serves as Deputy Director for Genomics at the Simons Center for Data Analysis, Simons Foundation, NYC. Her research focuses on computational biology, integrating diverse high-throughput genomic datasets to model molecular pathways in health and disease. Professor of Computer Science and Lewis-Sigler Institute for Integrative Genomics Deputy Director for Genomics, Simons Center for Data Analysis Research Interests: Troyanskaya’s work addresses challenges in bioinformatics, including algorithm development for gene expression analysis, regulatory network modeling, and disease mechanism interpretation. She combines computational methods with experimental validation using S. cerevisiae as a model organism. Scientific Trends: Recent publications emphasize single-cell multiomics, deep learning for transcriptional regulation, cancer immunotherapy design, and epigenomic analysis of immune responses. Key themes include computational modeling of genetic networks, disease-specific pathway analysis, and high-resolution omics frameworks. Collaborative roles in autism, Alzheimer’s, kidney disease, and cancer research Developed tools like HumanBase for data-driven predictions
Ruth Baker is a Professor of Applied Mathematics at the University of Oxford and a key member of the Mathematical Institute . Her work bridges mathematics, computational modeling, and biology to address complex developmental systems. Research Interests : Developing mathematical frameworks for cell and tissue-level biological processes Integrating computational and statistical methodologies with experimental data Exploring data-driven modeling for multidisciplinary collaboration Scientific Awards : Simons Investigator (2024-2029) Royal Society Wolfson Research Merit Award (2017-2022) FIMA (2021) FRSB (2020) Leverhulme Research Fellowship (2017-2019) London Mathematical Society Whitehead Prize (2014)
Katsuhito Yasuno is a Research Scientist in the Department of Neurosurgery at Yale School of Medicine. He works within the Gunel Lab, focusing on neurogenetic research related to brain disorders, vascular conditions, and tumors. His work involves genomic analyses and molecular studies to understand the genetic basis of various neurological conditions. Education: Postdoctoral Fellow, Japan Science and Technology Corporation (2008) Postdoctoral Fellow, Japan Biological Informatics Consortium (2006) Postdoctoral Fellow, Tokai University School of Medicine (2004) PhD in Theoretical Physics, Tokyo Institute of Technology (2002) MS in Theoretical Physics, Tokyo Institute of Technology (1999) BS in Physics, Tokyo Metropolitan University (1997) Dr. Yasuno's research spans multiple areas of neurogenetics and molecular neuroscience. His primary interests include epidemiologic factors and methods related to brain tumors (particularly glioblastoma and meningioma), intracranial aneurysms, nervous system diseases and malformations, and vascular diseases. His physics background contributes to sophisticated analytical approaches in genetic research. His publication record shows consistent contributions to understanding the genetic mechanisms underlying neurological disorders, with recent work focusing on meningioma genetics, brain malformations, and vascular disorders. The research demonstrates a progression from basic genetic discovery to translational applications, with particular emphasis on molecular pathways that could serve as therapeutic targets. Dr. Yasuno collaborates extensively with leading researchers in the field, most notably with Dr. Murat Günel (28 common publications) and Dr. Kaya Bilguvar (34 common publications). His work involves both computational analysis and laboratory validation of genetic findings. As part of the Gunel Lab, Dr. Yasuno contributes to the lab's three major research interests: developmental neurogenetic disorders, neurovascular disorders, and brain tumor biology. The lab utilizes advanced genomics techniques and bioinformatic analysis for gene discovery followed by functional studies.
Olga Kovalchuk is a Professor in the Department of Biological Sciences at the University of Lethbridge. She leads the Epigenetics of Health and Disease research laboratory, which is affiliated with the Southern Alberta Cancer Research Institute (SACRI) and Alberta Health Services/Alberta Cancer Foundation (AHS/ACF). Her research program has received significant funding including a $3.2 million Canada Foundation for Innovation (CFI) start-up grant and NSERC Discovery Grants. Dr. Kovalchuk's research focuses on the role of epigenetic mechanisms in health and disease, particularly in the context of radiation exposure and cancer. Her primary areas of investigation include epigenetic dysregulation in carcinogenesis, radiation epigenetics, DNA damage and repair mechanisms, and transgenerational effects of radiation exposure. She has made significant contributions to understanding how radiation-induced epigenetic changes affect genome stability, cancer development, and treatment responses. Analysis of her recent publications reveals a strong focus on microRNA regulation in cancer, sex-specific radiation responses, and the epigenetic basis of radiation-induced bystander effects. Her work demonstrates how epigenetic changes, particularly DNA methylation and microRNA expression patterns, mediate radiation responses in various tissues and can be transmitted across generations. Much of her research utilizes mouse models to investigate these mechanisms in vivo. Board of Governors Research Chair at University of Lethbridge CIHR Institute of Gender and Health Research Chair in New Perspectives in Gender, Sex and Health Canada Foundation for Innovation Start-up Funding ($3.2 Million) NSERC Discovery Grant recipient Editor's Choice Paper Award for research on radiation-induced bystander effects Cover Page feature for transgenerational radiation effects research Dr. Kovalchuk actively mentors numerous graduate students and postdoctoral fellows, with a research team comprising PhD students, MSc students, research assistants, and postdoctoral associates. Her laboratory collaborates extensively with researchers at MIT, Harvard University, and other institutions. She has secured significant grant funding including NSERC Discovery Grants and CFI start-up funds to support her research program investigating epigenetic mechanisms in radiation biology and cancer. Her laboratory, the Epigenetics of Health and Disease research group, maintains strong collaborations with the Southern Alberta Cancer Research Institute and has established partnerships with researchers across North America. Dr. Kovalchuk's work has important implications for understanding radiation risks, improving cancer therapies, and developing strategies to mitigate radiation damage.
Karen la Cour is a Professor at the Department of Public Health , University of Southern Denmark (SDU) , leading the Research Unit for User Perspectives & Community-based Interventions . She holds a PhD from Karolinska Institutet (2008) and an MSc in Occupational Therapy from Tufts University (1991) . Her career spans roles as Head of Research Groups , Affiliated Professor at Suunaas Hospital, Norway , and Research Director at REHPA . Academic Degrees: PhD (Karolinska Institutet), MSc (Tufts University) Current Role: Professor, SDU; Focus on community-based cancer rehabilitation and palliative care Research Interests center on coordination of rehabilitation and palliative care , advanced cancer patient quality of life , occupational therapy interventions , and community-based healthcare models . Her work emphasizes social equality , home-life adaptation , and co-production with patients and relatives . Selected Articles highlight her contributions to advanced cancer care , existential support programs , and resource-oriented interventions . Recent studies focus on virtual rehabilitation for dementia , young adult cancer survivors , and environmental restorative potential in palliative settings. Scientific Awards include the Jeppe Juhl Jensen Endowment Grant (2019) , European Cancer Rehabilitation Symposium Poster Prize (2016) , Ropox Prize (2015) , and a Fulbright Scholarship (1989) . Supervision involves mentoring PhD and Master’s students , with seven PhD graduates and four current students. Her projects include YATAC (young adult cancer survivors), COMPAS (socioeconomically disadvantaged cancer patients), and BALanSE (balance and quality of life in cancer care).
Rex Hung is an Associate Professor of Pathology at Harvard Medical School and serves as an Associate Pathologist at Massachusetts General Hospital . His academic career focuses on Bone and Soft Tissue Pathology , Cardiovascular Pathology , and Pulmonary Pathology , with significant contributions to cancer research.
Jacob Young, MD, is an Assistant Professor in the Department of Neurological Surgery at the University of California, San Francisco (UCSF) School of Medicine and a Principal Investigator in the UCSF Brain Tumor Center. His clinical practice focuses on neurosurgical management of adult brain tumors including gliomas, metastatic tumors, and meningiomas, utilizing advanced brain mapping techniques to preserve critical motor, language, and sensory functions during resection. Dr. Young's educational background includes a BS in Neuroscience from Duke University (2012), an MD from the University of Chicago Pritzker School of Medicine where he was elected to Alpha Omega Alpha Honor Medical Society (2017), and a neurosurgery residency at UCSF (2017-2024). His research program integrates laboratory investigations with clinical trials to address fundamental challenges in brain tumor treatment. His primary research interests center on understanding glioblastoma immune microenvironment dynamics and developing innovative therapeutic strategies. Key focus areas include: First-in-human clinical trials of novel immunotherapies Focused ultrasound-mediated blood-brain barrier disruption to enhance drug delivery Longitudinal molecular profiling of tumor evolution during treatment AI-driven tools for patient care navigation and clinical trial assessment Prospective outcomes research through the RANO resect group and NeuroPoint Alliance His work bridges fundamental tumor biology with translational applications to overcome treatment resistance. Analysis of Dr. Young's 15 most recent publications (2023-2025) reveals a strong emphasis on surgical innovation, tumor immunology, and molecular characterization. Key trends include: development of prognostic classification systems for resection extent, investigation of glioma-neuronal circuit interactions driving immunosuppression, and optimization of drug delivery strategies. His collaborative work within the RANO consortium establishes evidence-based surgical guidelines while his lab's focus on microenvironmental factors informs next-generation immunotherapies. Dr. Young has received significant recognition including: Chan-Zuckerberg Physician Scientist Fellowship (2021-2022) ASCO Young Investigator Award (2022-2023) Andrew J. Lockhart Focused Ultrasound Fellowship (2023) Multiple Harold Rosegay Teaching Awards from UCSF Howard Naffziger Award for Clinical Excellence His research is supported by NIH, NCI, Focused Ultrasound Foundation, and AANS grants. As lab director, Dr. Young mentors a diverse team including PhD candidates like Edward Valenzuela (DSCB program) and specialists in immunology and neuro-oncology. His lab participates in the RANO resect group, ENCRAM research program, and NeuroPoint Alliance to advance clinical protocols. Current projects include developing intraoperative focused ultrasound prototypes, single-cell analysis of tumor evolution, and AI tools for patient navigation through care pathways. Future work focuses on translating microenvironment discoveries into combination therapies targeting treatment resistance mechanisms.
Jennifer E Miller is an Associate Professor of Medicine (General Internal Medicine) and Biomedical Informatics & Data Science at Yale School of Medicine. She serves as Co-Director of the Program for Biomedical Ethics and holds leadership positions including Director of the Good Pharma Scorecard (an index that ranks pharmaceutical companies on bioethical performance) and Founder of Bioethics International. Her academic appointments reflect her interdisciplinary expertise spanning clinical medicine, ethics, and data science. Dr. Miller's research program focuses on critical ethical dimensions of biomedical innovation, with particular emphasis on ethics, equity and governance in drug, vaccine, and medical device research, development, and accessibility. She specializes in developing metrics to enhance accountability and social responsibility in the pharmaceutical industry. Her work examines clinical trial diversity, international research ethics, healthcare data sharing, and the implementation of ethical frameworks in medical product development. Through the Good Pharma Scorecard initiative, she has created a systematic approach to evaluating pharmaceutical company performance across multiple ethical dimensions including clinical trial transparency, diversity in research participation, and access to medicines. Analysis of Dr. Miller's recent publications (2021-2025) reveals a strong thematic focus on diversity and equity in clinical research, with particular attention to demographic representation in trials, ethical considerations in international trial site selection, and equitable access to newly approved drugs and vaccines. Her work bridges bioethics, health policy, and data science, creating measurable frameworks for assessing ethical performance in the pharmaceutical industry. The interdisciplinary nature of her research connects clinical medicine, public health, and corporate accountability, with direct implications for regulatory policy and industry practice. Appointment to World Economic Forum Center for the Fourth Industrial Revolution, Precision Medicine Council (2019) Appointment to World Economic Forum Biotechnology Council (2018) Appointment to World Economic Forum Futures Council (2017) Appointment to World Economic Forum Human Enhancement Working Group (2017) Fellow at Foundation Brocher for Ethical Issues in Global Population Health (2014) As Director of the Good Pharma Scorecard and Founder of Bioethics International, Dr. Miller leads initiatives that connect academic research with practical applications in industry ethics. Her work involves collaboration with pharmaceutical companies, regulatory agencies, and patient advocacy groups to develop and implement ethical standards in biomedical innovation. Through editorial roles at journals including Nature Medicine, The BMJ, and JAMA, she influences discourse on research ethics and scientific integrity. Dr. Miller is actively involved in advising and mentorship through her academic appointments at Yale, where she contributes to training the next generation of researchers in biomedical ethics and data science.
Fabio Zanini is an Associate Professor at the University of New South Wales (UNSW) , leading a research group focused on computational biology , single-cell approaches , and transcriptomic analysis across diseases like severe dengue , neonatal lung disease , cancer , and marine biology . He previously conducted postdoctoral research at Stanford University (2016-2019) and earned a PhD in Bioinformatics from the Max Planck Institute for Developmental Biology and the University of Tuebingen (2015). Current Affiliation: Group leader, UNSW Previous Training: Postdoc (Stanford), PhD (Max Planck/University of Tuebingen) His research spans single-cell RNA sequencing , computational virology , developmental cell biology , and bioinformatics tool development , with recent work on: Severe dengue progression (viral-host interactions, immune signatures) Lung development (endothelial cell diversity, hyperoxia-induced injury) Cancer genomics (mutant HSC clones, AZA therapy response) Marine biology (plankton transcriptomics, evolutionary analysis) Bioinformatics (HTSeq 2.0, northstar algorithm) Recent scientific awards include grants from the Chan Zuckerberg Initiative ($270,000), NIH R01 (multiple), ARC Discovery Grant , and NHMRC Ideas Grant . Notable contributions include: Northstar - Cell classification algorithm SpectralSeq - Hyperspectral-transcriptomic integration Tabula Muris - Mouse aging atlas He has supervised research into hematopoietic stem cell regulation , lung vascular development , and autophagy in viral infections , with collaborations across Stanford , University of Sydney , and Harvard .
Professor Charlotte Kloft is Head of the Department of Clinical Pharmacy & Biochemistry at the Institute of Pharmacy, Free University of Berlin since 2011, and spokesperson for the interdisciplinary Graduate Research Training Program PharMetrX 'Pharmacometrics and Computational Disease Modelling' since 2008. She previously served as Professor and Head of the Department of Clinical Pharmacy at Martin-Luther-University Halle-Wittenberg (2005-2011) and as Scientific Assistant/Senior Assistant at Freie Universität Berlin (1999-2005). Her academic credentials include a habilitation in Clinical Pharmacy from Freie Universität Berlin (2003) and a Dr. rer. nat. (summa cum laude) from the same institution (1997). She earned her license as a pharmacist in 1992 after completing pharmacy studies at Johannes Gutenberg-University, Mainz (1987-1991). Professor Kloft's research focuses on pharmacometrics, computational disease modeling, and therapeutic drug monitoring across multiple therapeutic areas. Her work bridges pharmaceutical sciences with clinical practice, with particular emphasis on personalized dosing strategies for oncology, antimicrobial resistance, and inflammatory bowel diseases. She has pioneered research in optimizing drug dosing through pharmacokinetic/pharmacodynamic modeling, with applications in both antibiotic and cancer therapies. Her recent publications demonstrate a strong evolution toward integrating advanced computational approaches with clinical pharmacology, including machine learning applications in pharmacometrics, personalized dosing strategies for biologics during pregnancy, and developing nationwide infrastructure for therapeutic drug monitoring in cancer therapy through the ON-TARGET study. Academic Center of Excellence of Pharsight (now Certara), USA (since 2000) Habilitationsreisestipendium of Dr. August and Dr. Anni Lesmüller-Stiftung (2002) Ernst-Reuter-Preis of Ernst-Reuter-Gesellschaft (1998) Joachim-Tiburtius-Preis of Berlin Senate (1998) Young Investigator Award of EORTC-PAMM (1997) Professor Kloft has successfully supervised numerous doctoral students whose research spans diverse areas including CAR-T cell therapy, antimicrobial resistance, inflammatory bowel disease treatment optimization, and pharmacokinetic modeling of novel therapeutic agents. Her research group has secured significant funding for projects including GlobalResist, ON-TARGET, ABIMMUNE, COMBINATORIALS, and TAIN. She leads a vibrant research ecosystem at the Free University of Berlin with strong collaborations across Europe and internationally, maintaining state-of-the-art laboratory facilities including Biosafety Level 2 certified labs for infectious disease research.
Dr. Kibret Mequanint is a full Professor at Western University's Department of Chemical and Biochemical Engineering, with cross-appointments in Biomedical Engineering. Holding a PhD from University of Stellenbosch and postdoctoral experience at Technical University of Darmstadt and McMaster University, his research bridges polymer science, materials engineering, and life sciences with applications in Biomaterials , Tissue Engineering , and Regenerative Medicine . His work spans both fundamental and translational research in cell-material interactions , polymer biomaterial design , and therapeutic radiation dosimeters , with technologies transferred to commercial applications. Leading scholar and educator with awards from NSERC, CIHR, and Western University Fellow of: American Institute for Medical and Biological Engineering (AIMBE), Ethiopian Academy of Sciences, International Union of Societies for Biomaterials Science and Engineering, Canadian Academy of Engineering Extensive editorial and panel service for NSERC, CIHR, and international journals His research program has produced over 170 refereed publications, focusing on conductive hydrogels , bioadhesives , and vascular tissue engineering . Recent work on endoscopy-deliverable bioadhesives and snake venom-derived hemostatic gels has attracted global media attention. He has served in leadership roles at the Canadian Biomaterials Society and university governance bodies including Senate and Board of Governors.
Tony Ingesson is a Senior Lecturer in the Department of Political Science at Lund University, specializing in intelligence analysis, counter-espionage, and military decision-making. With a background in the Swedish Armed Forces where he worked with technical data acquisition for airborne weapons systems and communications, he brings practical military experience to his academic work. His research interests span intelligence analysis methodologies, counterintelligence operations, deception and manipulation at tactical levels, clandestine communications, and industrial espionage. Ingesson has developed a particular expertise in how psychological mechanisms and biases influence intelligence analysis, as well as the historical connections between military conscription and democratization. His work bridges theoretical political science with practical security applications. Analysis of his recent publications reveals a strong focus on contemporary security challenges, particularly the intersection of traditional and emerging technologies in intelligence operations. His work examines how historical communication methods persist in modern conflicts, the evolving nature of espionage in high-trust societies like Sweden, and the application of intelligence analysis techniques to non-traditional fields such as precision oncology. Ingesson demonstrates consistent scholarly output across both academic journals and public-facing platforms like The Conversation, indicating his commitment to making complex security issues accessible to broader audiences. Ingesson actively participates in interdisciplinary research projects, including 'Clandestine Communications: Old Technologies, New Opportunities' and 'Greyzone genomics' at the Pufendorf IAS. His teaching portfolio encompasses political science methods, intelligence analysis techniques, counterterrorism, and deception studies, reflecting the breadth of his expertise. While specific details about student advising aren't provided in the available information, his role as Senior Lecturer indicates involvement in mentoring students through his teaching responsibilities. His research team involvement includes collaboration with researchers like Magnus Andersson on clandestine communications and David Gisselsson Nord on the intersection of genomics and security. These collaborations demonstrate his ability to bridge disciplinary boundaries while maintaining focus on core intelligence and security issues.
Professor Paul Rayson is a Professor of Natural Language Processing in the School of Computing & Communications at Lancaster University, UK. He serves as Director of the UCREL (University Centre for Computer Corpus Research on Language) interdisciplinary research centre and is affiliated with multiple research institutes including Security Lancaster, the Lancaster Centre for Digital Humanities, and the Data Science Institute. Education: PhD in Computer Science, Lancaster University (2003) BSc (Hons) Computer Science and Mathematics, Lancaster University (1990) Professor Rayson's research focuses on semantic multilingual Natural Language Processing (NLP) in challenging linguistic environments with noisy language data, including historical texts, learner language, speech, email, and other computer-mediated communication. His work spans applications in dementia detection, mental health analysis, online child protection, cyber security, learner dictionaries, and text mining of biomedical literature, historical corpora, and financial narratives. He has developed semantic tagging tools like USAS (UCREL Semantic Analysis System) and Wmatrix for corpus analysis. Major Awards and Honors: FHEA (Fellow of the Higher Education Academy) MBCS (Member of the British Computer Society) Professor Rayson has supervised numerous PhD students in NLP and corpus linguistics, with eight current students and seven completed doctorates. He has led or co-investigated multiple major research projects including the £3.5m ESRC-funded Centre for Corpus Approaches to Social Science (CASS), the National Corpus of Contemporary Welsh, and projects related to mental health forums, financial narrative analysis, and cyber security. His research has been supported by ESRC, EPSRC, and other funding bodies. As Director of UCREL, he oversees research in corpus linguistics and NLP. He is also active in the Cyber Security Research Centre, Digital Health Group, and multiple Data Science Institute initiatives. His lab has developed several widely-used NLP tools including CLAWS for English POS tagging, USAS semantic analysis system, Wmatrix corpus analysis tool, and the Variant Detector (VARD) for historical texts.
Prof. Dr. Norbert Sewald, Chair of Organic and Bioorganic Chemistry at Bielefeld University, is a leading figure in Bioorganic Chemistry , Chemical Biology , and Enzymatic Halogenation . As head of the Organic and Bioorganic Chemistry Group at the Center for Biotechnology (CeBiTec), he drives research on natural products and drug conjugates. Full Professor, Bielefeld University (since 1999) Founding Coordinator, International Graduate School of Chemistry and Biochemistry (2001-2003) Chairman, Institute of Biochemistry and Bioengineering at CeBiTec (2006-2008) Dean, Department of Chemistry (2008-2011) Chairman, Max-Bergmann-Kreis e.V. (since 2010) Coordinator, Marie Skłodowska-Curie Training Networks (MAGICBULLET, 2015-2018; Magicbullet::reloaded, 2020-2023) His research focuses on halogenases for mild peptide bromination, cryptophycin-based tumor targeting , and bioactive natural products from African flora. Collaborative projects span antiplasmodial agents , antibacterial compounds , and neurodegenerative disease inhibitors . Recent work highlights include: Enzymatic halogenation cascades Click-to-release drug conjugates Fluorescent probes for amyloid detection Key affiliations: Faculty of Chemistry Center for Biotechnology (CeBiTec) European Peptide Society (Scientific Affairs Officer, 2016-) Leibniz Institute of Plant Biochemistry (Scientific Advisory Board, 2010-2017)
